3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasms
2
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Newly Diagnosed Glioblastoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Melanoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Trastuzumab
62
Paclitaxel
57
Cyclophosphamide
44
pembrolizumab
34
Fulvestrant
34
Capecitabine
29
Carboplatin
26
Docetaxel
23
Letrozole
22
Doxorubicin
19
palbociclib
16
abemaciclib
16
pertuzumab
15
durvalumab
14
Filgrastim
13
Everolimus
13
ribociclib
12
Lapatinib
12
Gemcitabine
12
exemestane
11
eribulin
11
Vinorelbine
11
Albumin-Bound Paclitaxel
11
Bevacizumab
10
trastuzumab deruxtecan
9
neratinib
9
fludarabine
9
Taxes
9
Radiotherapy
9
Peripheral Blood Stem Cell Transplantation
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Breast Neoplasms
×
efineptakin alfa
×
Clear all
NCT03752723
2024-03-05
KEYNOTE-899
Genexine, Inc.
Phase 1/2
Completed
84 enrolled